Literature DB >> 15982995

Influence of age and gender on risperidone plasma concentrations.

Wolfgang Aichhorn1, Ulrike Weiss, Josef Marksteiner, Georg Kemmler, Thomas Walch, Gerald Zernig, Renate Stelzig-Schoeler, Christoph Stuppaeck, Christian Geretsegger.   

Abstract

There is limited information on gender- and age-specific effects on plasma concentrations of risperidone and its active metabolite, 9-hydroxyrisperidone. The present study investigated dose- and weight-adjusted plasma concentrations of risperidone and its metabolite in three age groups (45 years, 45-60 years, over 60 years). Gender-specific differences were examined in the whole sample and for the premenopausal subgroup. One hundred and twenty-nine patients (18-93 years) were included in the study, 52 (40%) male and 77 (60%) female. Concentrations of risperidone and 9-hydroxyrisperidone were measured at steady-state by high-performance liquid chromatography with electrochemical detection (HPLC-ED). When total plasma concentrations (risperidone plus 9-hydroxyrisperidone) were adjusted for daily maintenance dose (ng/mL/mg C/D ratio), significant differences between all age groups were found. We found a mean increase of the C/D ratio by 34.8% per decade in patients older than 42 years. No significant sex-related differences in the average plasma concentrations were observed for the whole sample and for the premenopausal subgroup. This study shows clear evidence of higher risperidone total plasma concentrations for patients over 40 years of age. This linear increase (over 30% per decade) may then lead to an increased incidence of adverse effects in elderly patients.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15982995     DOI: 10.1177/0269881105053306

Source DB:  PubMed          Journal:  J Psychopharmacol        ISSN: 0269-8811            Impact factor:   4.153


  20 in total

1.  Serum concentrations of paliperidone versus risperidone and clinical effects.

Authors:  Yasmin Nazirizadeh; Friederike Vogel; Wolfgang Bader; Ekkehard Haen; Bruno Pfuhlmann; Gerhard Gründer; Michael Paulzen; Markus Schwarz; Gerald Zernig; Christoph Hiemke
Journal:  Eur J Clin Pharmacol       Date:  2010-04-01       Impact factor: 2.953

2.  Genotyping as a Key Element of Sample Size Optimization in Bioequivalence of Risperidone Tablets.

Authors:  Ying Chen; Yang Deng; Miao Yan; Zhenyan Hou; Yao Li; Bikui Zhang; Hualin Cai
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2018-08       Impact factor: 2.441

3.  Population pharmacokinetic analysis for risperidone using highly sparse sampling measurements from the CATIE study.

Authors:  Yan Feng; Bruce G Pollock; Kim Coley; Stephen Marder; Del Miller; Margaret Kirshner; Manickam Aravagiri; Lon Schneider; Robert R Bies
Journal:  Br J Clin Pharmacol       Date:  2008-07-31       Impact factor: 4.335

Review 4.  [Differences between men and women in side effects of second-generation antipsychotics].

Authors:  W Aichhorn; A B Whitworth; E M Weiss; H Hinterhuber; J Marksteiner
Journal:  Nervenarzt       Date:  2007-01       Impact factor: 1.214

Review 5.  Second-generation antipsychotics: is there evidence for sex differences in pharmacokinetic and adverse effect profiles?

Authors:  Wolfgang Aichhorn; Alexandra B Whitworth; Elisabeth M Weiss; Josef Marksteiner
Journal:  Drug Saf       Date:  2006       Impact factor: 5.606

6.  Possible drug-drug interaction between quetiapine and lamotrigine--evidence from a Swedish TDM database.

Authors:  Marine L Andersson; Linda Björkhem-Bergman; Jonatan D Lindh
Journal:  Br J Clin Pharmacol       Date:  2011-07       Impact factor: 4.335

7.  Genetics-Based Population Pharmacokinetics and Pharmacodynamics of Risperidone in a Psychiatric Cohort.

Authors:  Frederik Vandenberghe; Monia Guidi; Eva Choong; Armin von Gunten; Philippe Conus; Chantal Csajka; Chin B Eap
Journal:  Clin Pharmacokinet       Date:  2015-12       Impact factor: 6.447

8.  Influence of risperidone on balance control in young healthy individuals.

Authors:  Philippe Corbeil; Julien Rodrigue; Martin Simoneau; Henri Cohen; Emmanuelle Pourcher
Journal:  Psychopharmacology (Berl)       Date:  2012-01-11       Impact factor: 4.530

Review 9.  Secondary effects of antipsychotics: women at greater risk than men.

Authors:  Mary V Seeman
Journal:  Schizophr Bull       Date:  2008-04-09       Impact factor: 9.306

10.  Population pharmacokinetic modeling of risperidone and 9-hydroxyrisperidone to estimate CYP2D6 subpopulations in children and adolescents.

Authors:  Catherine M T Sherwin; Shannon N Saldaña; Robert R Bies; Michael G Aman; Alexander A Vinks
Journal:  Ther Drug Monit       Date:  2012-10       Impact factor: 3.681

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.